Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 2
1953 1
1957 3
1958 1
1961 2
1962 1
1963 5
1964 5
1965 2
1966 1
1967 1
1969 1
1971 1
1972 2
1973 1
1974 1
1979 1
1980 1
1981 1
1982 3
1983 2
1984 5
1985 5
1986 10
1987 13
1988 9
1989 9
1990 12
1991 9
1992 20
1993 20
1994 15
1995 20
1996 21
1997 21
1998 26
1999 31
2000 35
2001 37
2002 37
2003 65
2004 77
2005 102
2006 122
2007 121
2008 160
2009 177
2010 198
2011 280
2012 288
2013 338
2014 398
2015 432
2016 520
2017 552
2018 591
2019 659
2020 797
2021 904
2022 1001
2023 976
2024 1122
2025 1240
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,316 results

Results by year

Filters applied: . Clear all
Page 1
Author Correction: Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome.
Su H, Yang F, Fu R, Trinh B, Sun N, Liu J, Kumar A, Baglieri J, Siruno J, Le M, Li Y, Dozier S, Nair A, Filliol A, Sinchai N, Rosenthal SB, Santini J, Metallo CM, Molina A, Schwabe RF, Lowy AM, Brenner DA, Sun B, Karin M. Su H, et al. Nature. 2025 Jul;643(8071):E10. doi: 10.1038/s41586-025-09285-4. Nature. 2025. PMID: 40533566 Free PMC article. No abstract available.
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.
Zhao C, Zhang Y, Wang G, Zheng J, Chen W, Lu Z, Zhuang L, Gu S, Han L, Zheng Z, Yu Z, Yang Y, Sun H, Wei X, Cheng Y, Lin H, Zhu B, Wu G, Lei K, Wang W, Wang Y, Chen K, Xu X, Zheng C, Bi Y, Ding S, Zhang J, Li W, Liu H, Wang J, Liu X, Du Y, Cai L, Wang J, Luo Z, Xing B, Shen J, Yang L, Wu J, Jiang O, Peng Z, Liu X, Cao B, Shen L, Xu A, Li A, Chen S, Fu T, Chen J, Jin C, Zhang L, Lv J, Zhang C, Zhang X, Wang Y, Su H, Zhou Q, Gai W, Xie L, Xu J. Zhao C, et al. Signal Transduct Target Ther. 2025 Aug 6;10(1):249. doi: 10.1038/s41392-025-02333-5. Signal Transduct Target Ther. 2025. PMID: 40769977 Free PMC article. Clinical Trial.
An overview of post-stroke disability.
Chen CH, Chang TY, Sung PS, Su HC, Chou CH, Tung H, Tsai LK, Tang SC, Jeng JS. Chen CH, et al. J Formos Med Assoc. 2025 Nov 6:S0929-6646(25)00583-2. doi: 10.1016/j.jfma.2025.10.038. Online ahead of print. J Formos Med Assoc. 2025. PMID: 41203544 Free article. Review.
Metformin as antiviral therapy protects hyperglycemic and diabetic patients.
Wang X, Zheng X, Ge H, Cui N, Lin L, Yue M, Zhu C, Zhou Q, Song P, Shang X, Wang R, Wang Z, Wang Z, Zhang Y, Yin X, Yang L, Su H, Li H, Liu W. Wang X, et al. mBio. 2025 Jun 11;16(6):e0063425. doi: 10.1128/mbio.00634-25. Epub 2025 May 20. mBio. 2025. PMID: 40391966 Free PMC article.
10,316 results
You have reached the last available page of results. Please see the User Guide for more information.